Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
191 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape. H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 6, 14, 1, 30 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively.Influenza A Virus, H5N1 Subtype Infections. Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Influenza A Virus, H5N1 Subtype Infections Overview 9 Therapeutics Development 10 Pipeline Products for Influenza A Virus, H5N1 Subtype Infections - Overview 10 Pipeline Products for Influenza A Virus, H5N1 Subtype Infections - Comparative Analysis 11 Influenza A Virus, H5N1 Subtype Infections - Therapeutics under Development by Companies 12 Influenza A Virus, H5N1 Subtype Infections - Therapeutics under Investigation by Universities/Institutes 15 Influenza A Virus, H5N1 Subtype Infections - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Influenza A Virus, H5N1 Subtype Infections - Products under Development by Companies 19 Influenza A Virus, H5N1 Subtype Infections - Products under Investigation by Universities/Institutes 23 Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development 24 Akshaya Bio Inc 24 Altimmune Inc 25 Antigen Express Inc 26 Aphios Corp 27 BioDiem Ltd 28 BiondVax Pharmaceuticals Ltd 29 CEL-SCI Corp 30 Cocrystal Pharma Inc 31 Emergent BioSolutions Inc 32 Gemmus Pharma Inc 33 GlaxoSmithKline Plc 34 Hemispherx Biopharma Inc 35 iBio Inc 36 Inovio Pharmaceuticals Inc 37 Johnson & Johnson 38 Kineta Inc 39 Lakewood-Amedex Inc 40 Medicago Inc 41 Medigen Vaccine Biologics Corp. 42 Microbiotix Inc 43 NanoBio Corp 44 Nanotherapeutics Inc 45 NanoViricides Inc 46 NewLink Genetics Corp 47 OPKO Health Inc 48 PaxVax Inc 49 PeptiDream Inc 50 Protein Sciences Corp 51 Shionogi & Co Ltd 52 Takeda Pharmaceutical Company Ltd 53 TechnoVax Inc 54 TGV-Laboratories 55 Vaxart Inc 56 Vaxine Pty Ltd 57 VaxInnate Corp 58 Visterra Inc 59 Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment 60 Assessment by Monotherapy Products 60 Assessment by Combination Products 61 Assessment by Target 62 Assessment by Mechanism of Action 64 Assessment by Route of Administration 66 Assessment by Molecule Type 68 Drug Profiles 70 A-06 - Drug Profile 70 AE-443p - Drug Profile 71 Alferon LDO - Drug Profile 72 APP-0205 - Drug Profile 74 APP-309 - Drug Profile 75 AT-301 - Drug Profile 76 CEL-1000 - Drug Profile 77 CHOS-05 - Drug Profile 79 DPC-005 - Drug Profile 80 FBF-001 - Drug Profile 81 Gamma-Flu - Drug Profile 82 GP-1001 - Drug Profile 83 GP-1002 - Drug Profile 84 GP-1681 - Drug Profile 85 GREFLU/VIE - Drug Profile 87 HAI-05 - Drug Profile 88 HB-36.6 - Drug Profile 89 Influ-nRNA - Drug Profile 90 influenza [strain A/H5N1] (split virion) vaccine - Drug Profile 91 influenza [strain A/H5N1] (virus like particle) vaccine 2 - Drug Profile 92 influenza [strain A/H5N1] vaccine - Drug Profile 95 influenza [strain A/H5N1] vaccine - Drug Profile 96 influenza [strain A/H5N1] vaccine - Drug Profile 97 influenza [strain A/H5N1] vaccine - Drug Profile 99 influenza [strain A/H5N1] vaccine - Drug Profile 100 influenza [strain A/H5N1] vaccine - Drug Profile 101 influenza [strain A/H5N1] vaccine - Drug Profile 102 influenza [strain A/H5N1] vaccine - Drug Profile 103 influenza [strain A/H5N1] vaccine - Drug Profile 104 influenza [strain A/H5N1] vaccine 2 - Drug Profile 105 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 106 influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 107 influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile 108 influenza [strains A/H5N1 + A/H7N2 + A/H9N2] (virus like particle) vaccine - Drug Profile 109 influenza vaccine - Drug Profile 110 INO-3510 - Drug Profile 111 JNJ-872 - Drug Profile 113 KD-295 - Drug Profile 115 KIN-1148 - Drug Profile 116 Lalistat - Drug Profile 117 M-001 - Drug Profile 118 MBX-2329 - Drug Profile 123 MBX-2546 - Drug Profile 124 Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection - Drug Profile 125 MV-4 - Drug Profile 126 MVAH-5HA - Drug Profile 127 Nasovax - Drug Profile 128 NVINF-1 - Drug Profile 130 NVINF-2 - Drug Profile 134 OrniFlu - Drug Profile 137 PanBlok - Drug Profile 138 PD-001 - Drug Profile 141 PNSIA-28 - Drug Profile 142 PNSIA-49 - Drug Profile 143 PXVX-0103 - Drug Profile 144 rintatolimod - Drug Profile 145 S-033188 - Drug Profile 154 Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile 156 Small Molecules to Activate Sirtuin for Influenza - Drug Profile 157 Small Molecules to Inhibit PB2 for Influenza - Drug Profile 158 Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 159 Synthetic Peptides for Viral Infections - Drug Profile 160 TVX-003 - Drug Profile 161 VAX-161C - Drug Profile 162 VGX-3400X - Drug Profile 163 VH-244 - Drug Profile 164 VIS-410 - Drug Profile 165 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects 168 Influenza A Virus, H5N1 Subtype Infections - Discontinued Products 174 Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones 175 Featured News & Press Releases 175 Appendix 185 Methodology 185 Coverage 185 Secondary Research 185 Primary Research 185 Expert Panel Validation 185 Contact Us 185 Disclaimer 186
List of Tables
Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2016 15 Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections - Comparative Analysis, H2 2016 16 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Late Stage Development, H2 2016 21 Comparative Analysis by Clinical Stage Development, H2 2016 22 Comparative Analysis by Early Stage Development, H2 2016 23 Products under Development by Companies, H2 2016 24 Products under Development by Companies, H2 2016 (Contd..1) 25 Products under Development by Companies, H2 2016 (Contd..2) 26 Products under Development by Companies, H2 2016 (Contd..3) 27 Products under Investigation by Universities/Institutes, H2 2016 28 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2016 29 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2016 30 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Antigen Express Inc, H2 2016 31 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Aphios Corp, H2 2016 32 Influenza A Virus, H5N1 Subtype Infections - Pipeline by BioDiem Ltd, H2 2016 33 Influenza A Virus, H5N1 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H2 2016 34 Influenza A Virus, H5N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2016 35 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2016 36 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Emergent BioSolutions Inc, H2 2016 37 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H2 2016 38 Influenza A Virus, H5N1 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 39 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Hemispherx Biopharma Inc, H2 2016 40 Influenza A Virus, H5N1 Subtype Infections - Pipeline by iBio Inc, H2 2016 41 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2016 42 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2016 43 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Kineta Inc, H2 2016 44 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H2 2016 45 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medicago Inc, H2 2016 46 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp., H2 2016 47 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Microbiotix Inc, H2 2016 48 Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoBio Corp, H2 2016 49 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Nanotherapeutics Inc, H2 2016 50 Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoViricides Inc, H2 2016 51 Influenza A Virus, H5N1 Subtype Infections - Pipeline by NewLink Genetics Corp, H2 2016 52 Influenza A Virus, H5N1 Subtype Infections - Pipeline by OPKO Health Inc, H2 2016 53 Influenza A Virus, H5N1 Subtype Infections - Pipeline by PaxVax Inc, H2 2016 54 Influenza A Virus, H5N1 Subtype Infections - Pipeline by PeptiDream Inc, H2 2016 55 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Protein Sciences Corp, H2 2016 56 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Shionogi & Co Ltd, H2 2016 57 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 58 Influenza A Virus, H5N1 Subtype Infections - Pipeline by TechnoVax Inc, H2 2016 59 Influenza A Virus, H5N1 Subtype Infections - Pipeline by TGV-Laboratories, H2 2016 60 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxart Inc, H2 2016 61 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxine Pty Ltd, H2 2016 62 Influenza A Virus, H5N1 Subtype Infections - Pipeline by VaxInnate Corp, H2 2016 63 Influenza A Virus, H5N1 Subtype Infections - Pipeline by Visterra Inc, H2 2016 64 Assessment by Monotherapy Products, H2 2016 65 Assessment by Combination Products, H2 2016 66 Number of Products by Stage and Target, H2 2016 68 Number of Products by Stage and Mechanism of Action, H2 2016 70 Number of Products by Stage and Route of Administration, H2 2016 72 Number of Products by Stage and Molecule Type, H2 2016 74 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2016 173 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects (Contd..1), H2 2016 174 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects (Contd..2), H2 2016 175 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects (Contd..3), H2 2016 176 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects (Contd..4), H2 2016 177 Influenza A Virus, H5N1 Subtype Infections - Dormant Projects (Contd..5), H2 2016 178 Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, H2 2016 179
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
